Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11767364 TL1A antibodies and methods of treatment

Patent 11767364 was granted and assigned to Bristol-Myers Squibb on September, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Bristol-Myers Squibb

Current Assignee

Bristol-Myers Squibb

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Guodong Chen

Achal Mukundrao Pashine

Date of Patent

September 26, 2023

Patent Application Number

17188025

Date Filed

March 1, 2021

Patent Citations

US Patent 10072088 Anti-BCMA antibodies and uses thereof

US Patent 7317091 Optimized Fc variants

US Patent 8101720 Immunoglobulin insertions, deletions and substitutions

US Patent 9556277 Method of treating a TL1A-associated disease or disorder with human antibodies to TL1A

US Patent 9683998 Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof

US Patent 10626180 Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease

Patent Primary Examiner

Patent abstract

Disclosed are antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11767364 TL1A antibodies and methods of treatment

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool